Reuters -- Germany’s Merck KGaA (MRCG.DE) has resubmitted its request for U.S. regulatory approval for its cladribine drug as it tries to catch up in the race for the first multiple sclerosis (MS) pill.
Reuters -- Germany’s Merck KGaA (MRCG.DE) has resubmitted its request for U.S. regulatory approval for its cladribine drug as it tries to catch up in the race for the first multiple sclerosis (MS) pill.
